Curated Wealth Partners LLC Has $1.03 Million Stock Holdings in Labcorp Holdings Inc. $LH

Curated Wealth Partners LLC trimmed its holdings in Labcorp Holdings Inc. (NYSE:LH) by 5.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,915 shares of the medical research company’s stock after selling 238 shares during the quarter. Curated Wealth Partners LLC’s holdings in Labcorp were worth $1,028,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in LH. Golden State Wealth Management LLC lifted its stake in Labcorp by 88.1% in the first quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company’s stock valued at $26,000 after buying an additional 52 shares during the period. North Capital Inc. acquired a new position in shares of Labcorp during the 1st quarter valued at $27,000. TruNorth Capital Management LLC acquired a new position in shares of Labcorp during the 1st quarter valued at $28,000. Larson Financial Group LLC lifted its position in shares of Labcorp by 140.4% during the 1st quarter. Larson Financial Group LLC now owns 125 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 73 shares during the period. Finally, Financial Gravity Asset Management Inc. acquired a new position in shares of Labcorp during the first quarter valued at about $31,000. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp Stock Performance

Shares of Labcorp stock opened at $280.02 on Wednesday. The company has a market cap of $23.27 billion, a PE ratio of 30.91, a price-to-earnings-growth ratio of 1.77 and a beta of 0.89. Labcorp Holdings Inc. has a 52 week low of $209.38 and a 52 week high of $289.20. The business has a 50 day moving average price of $275.89 and a 200-day moving average price of $256.69. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.61.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $4.35 EPS for the quarter, topping the consensus estimate of $4.14 by $0.21. The firm had revenue of $3.53 billion during the quarter, compared to the consensus estimate of $3.49 billion. Labcorp had a return on equity of 15.45% and a net margin of 5.66%.The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.94 earnings per share. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS. Equities analysts anticipate that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 11th. Stockholders of record on Wednesday, November 26th will be issued a $0.72 dividend. The ex-dividend date is Wednesday, November 26th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s dividend payout ratio is currently 31.79%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LH shares. Hsbc Global Res lowered shares of Labcorp from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. UBS Group upped their price target on Labcorp from $282.00 to $305.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Truist Financial set a $320.00 target price on Labcorp in a research report on Tuesday. Morgan Stanley upped their target price on Labcorp from $283.00 to $306.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Finally, HSBC lowered Labcorp from a “buy” rating to a “hold” rating and set a $260.00 target price on the stock. in a research report on Thursday, July 10th. Ten equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $292.83.

Insider Activity

In other Labcorp news, Director Dwight Gary Gilliland sold 2,000 shares of the stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $264.95, for a total value of $529,900.00. Following the completion of the sale, the director owned 6,656 shares in the company, valued at approximately $1,763,507.20. This trade represents a 23.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Adam H. Schechter sold 5,643 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $266.78, for a total transaction of $1,505,439.54. Following the completion of the sale, the chief executive officer owned 93,319 shares of the company’s stock, valued at approximately $24,895,642.82. This trade represents a 5.70% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,046 shares of company stock worth $4,074,692. Company insiders own 0.84% of the company’s stock.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.